ClinicalTrials.gg
RecruitingNCT06298071Updated Jan 8, 2026

A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.

A Phase 1 interventional study of SIBP-R002 and SIBP-R002 in Gout, sponsored by Shanghai Institute Of Biological Products. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Shanghai Institute Of Biological Products (part of Sinopharm) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Mar 2023, registered Feb 2024).
  • Started Mar 2023; still recruiting 3 years 8 months later.
Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

To evaluate the safety and tolerability of peguricase for injection with methotrexate in patients with gout who remain uncontrolled after standardized treatment with conventional uric acid-lowering drugs, to determine the recommended dose for phase II clinical trials, and to provide basis for formulation of administration regimen for phase II clinical trials.

Read the detailed description

To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic characteristics, and initial efficacy of single and multiple dosing of peguricase for injection with methotrexate in patients with gout who remain uncontrolled after standardized treatment with conventional uric acid-lowering drugs.

This study is a phase Ib single and multiple dosing, dose-increasing. Three dose groups of 4, 8 or 12 mg were planned, then exploring the most appropriate dose for phase II clinical trials, and to provide basis for formulation of administration regimen for phase II clinical trials.

02

Conditions studied

  • Gout

Browse trials for

Keywords

  • Uncontrolled gout
  • Peguricase for injection
  • Safety
  • Tolerability
  • Efficacy
03

In context

Gout

345 studies on the registry are indexed under Gout; 49 are open to participants now.

This study's planned enrollment of 36 is below the median of 83 across 286 interventional studies indexed under Gout.

Browse Gout studies →

Lead sponsor

Shanghai Institute Of Biological Products is the lead sponsor of 34 studies on the registry; 14 are open to participants now.

First submitted after Shanghai Institute Of Biological Products became part of Sinopharm.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Willing and able to give .
  • Male and female aged between 18 and 70 years old , regardless of gender.
  • Male weight ≥50 kg, female weight ≥45 kg, (BMI) in the range of (19-30) kg/m2 (including 19 and 30);
  • The clinical diagnosis of gout met the criteria of American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) in 2015,patients were in non-acute attack at screening or at least 2 weeks after complete remission of acute attack, and sUA ≥420 μmol/L at screening;
  • Patients whose serum uric acid level could not reach the target after standard treatment with conventional uric acid-lowering drugs or who were or intolerant to conventional uric acid-lowering drugs;
  • Patients who were willing to stop taking any uric-acid-lowering drug at least 7 days before using methotrexate during the run-in period;
  • Could tolerate the prescribed dose of methotrexate during the run-in period;
  • Patients were able to attend and complete the visit on time.

Exclusion criteria

Exclusion Criteria:

  • Patients had active systemic infection within 2 weeks before enrollment,including an infection for which treatment was being received;
  • Having a chronic or recurrent infection, such as recurrent pneumonia or chronic bronchitis; Patients with active or severe lung disease or pulmonary insufficiency on chest imaging, or current pulmonary fibrosis or bronchiectasis;
  • Patients who are on anti-TB treatment or have active TB;
  • Diagnosis of osteomyelitis;
  • Ongoing or long-term use of immune system modulating drugs, such as methotrexate, mercaptopurine, mycophanolate, long-term use (≥3 months) of prednisone ≥10 mg/ day or equivalent dose of ; Or have a history of transplant surgery requiring long-term immunotherapy; Or a known history of disease, allergic disease;
  • Known allergy to recombinant proteins or porcine products, or history of allergy to uricase, pegylated products, corticosteroids and antihistamines, or known intolerance to methotrexate, fexofenadine, acetaminophen or to methotrexate, fexofenadine, acetaminophen;
  • Patients who are known to be intolerant to all gout attack management regiments (participants must be able to tolerate at least one: Colchicine and/or Nsaids and/or Prednisone 0.5 mg/kg daily;
  • Patients who have previously been treated with pegyluricase or other recombinant uricase, or who have been treated with other pegylated biological products;
  • Participation in other clinical study with a drug intervention within 4 weeks before initiation of methotrexate or the drug was still in the elimination phase before screening (within 5 half-lives), whichever is older;
  • Patients with chronic liver disease such as hepatitis, cirrhosis, alcoholic liver disease;
  • Patients have unstable angina, severe arrhythmias requiring drug intervention, congestive heart failure ( grade≥Ⅱ), uncontrolled hypertension (over 150/95 mmHg), poor glycemic control in diabetics ( ≥7%), acute stroke, Severe or chronic hemorrhagic digestive disease, pleural and abdominal effusion;
  • A history of hypoxanthine-guanine phosphoribosyltransferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome;
  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency or G6PD test values below the lower limit of normal;
  • Estimated (eGFR) ≤40 mL/min/1.73m2, or currently receiving dialysis, or end-stage renal disease (CKD4-5);
  • (ALT) or aspartate aminotransferase (AST) above the value or albumin below the lower limit of normal value during screening (before methotrexate treatment);
  • Use of any blood component, short-acting or long-acting growth factor drugs within 14 days prior to screening, or white blood cell count \< 4×109/L, hematopoietic volume \< 32%, or count \< 75×109/L;
  • Receiving anticoagulant therapy or (INR) > 1.5×ULN or activated partial thromboplastin time (APTT) > 1.5×ULN before enrollment;
  • Receiving systemic or local radiotherapy for tumors, or history of within 5 years other than non-melanoma skin cancer or in situ carcinoma of cervix;
  • Any acute illness that was considered by the investigator to be likely to affect the study occurred within 1 month before screening;
  • Donated (or lost) blood and donated (or lost) ≥400 mL or received blood transfusion within 3 months before screening;
  • If any one of the five serological tests of was positive except for hepatitis B surface antibody, or antibody positive, treponema pallidum antibody positive or antibody positive in serum virology examination;
  • History of drug or substance abuse, or a positive drug screening test;
  • History of alcohol abuse in the 3 months before screening [drinking more than 14 units of alcohol per week (1 unit ≈360 mL of beer)] or 45 mL of 40% spirits or 150 mL of wine)]; or positive alcohol breath test on admission;
  • Lactating women, as well as male participants (or their partners) or female participants 30 days before the study to the end of the study, who have plans for pregnancy or sperm or egg donation within 6 months and are unwilling to take effective measures;
  • Patients have serious mental and psychological disorders, cognitive disorders and the existence of a history of mental illness.
  • The investigator considered it inappropriate to participate in the study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Group 1

    Injection; strength: 4mg.

    Drug: SIBP-R002 · Drug: Methotrexate

  • Experimental
    Group 2

    Injection; strength: 8mg.

    Drug: SIBP-R002 · Drug: Methotrexate

  • Experimental
    Group 3

    Injection; strength: 12mg.

    Drug: SIBP-R002 · Drug: Methotrexate

Interventions

  • DrugSIBP-R002

    Injection; strength: 4mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.

    Also known as: Peguricase for injection

  • DrugSIBP-R002

    Injection; strength: 8mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.

    Also known as: Peguricase for injection

  • DrugSIBP-R002

    Injection; strength: 12mg. Each group consists of 12 participants. Firstly, 4 sentinel participants were enrolled in the single dose phase of peruricase for injection and methotrexate. After the sentinel participants completed a 5-day safety observation of the single dose, the remaining 8 participants in this group can be enrolled simultaneously. If there are no special circumstances, the participants in this group will enter the multi-dose stage of peruricase for injection combined with methotrexate within 2-4 weeks after completing a single dose.

    Also known as: Peguricase for injection

  • Combination drugs: Methotrexate, dose15 mg, oral.

06

What researchers measure

Primary outcomes

  1. AE(Adverse Events)

    That is adverse events, any adverse events that occurred to the participant during the study period.

    Time frame: 14 weeks after the first dose

  2. SAE(Serious Adverse Events)

    That is serious adverse events, any serious adverse events that occurred to the participant during the study period.

    Time frame: 14 weeks after the first dose

  3. AUC(Area Under The Plasma Concentration Versus Time Curve)

    It shows the degree to which a drug is absorbed and used in the body

    Time frame: 14 weeks after the first dose

  4. Cmax(Peak Plasma Concentration)

    It shows the highest plasma concentration of a drug that can be achieved after administration.

    Time frame: 14 weeks after the first dose

  5. Tmax(Peak Time)

    That is peak time of drug action, it shows the time required to reach the maximum concentration on the participant plasma concentration curve after administration.

    Time frame: 14 weeks after the first dose

  6. T ½ (Terminal elimination half-life)

    It reflects how quickly the drug is eliminated from the body.

    Time frame: 14 weeks after the first dose

  7. CL (Clearance Rate)

    Apparent volume of drug distribution removed from the body per unit time.

    Time frame: 14 weeks after the first dose

  8. ADA (Anti-uricase Antibody, Anti-PEG Antibody, Anti-PEG-uricase Antibody)

    The incidence of anti-drug antibody.

    Time frame: 14 weeks after the first dose

  9. NAb (Anti-PEG-uricase Neutralizing Antibody)

    The incidence of neutralizing antibody.

    Time frame: 14 weeks after the first dose

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06298071
Collaborators
The First Affiliated Hospital of Bengbu Medical University, The First Affiliated Hospital of Henan University of Science and Technology
Responsible party
Sponsor
First posted
Mar 7, 2024
Start date
Mar 3, 2023
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jan 8, 2026

Study contacts

Dandan Chen, Master
Contact
ddchen.sh@sinopharm.com
86-021-62800991
Chaorong Xu, Master
Contact
xuchaorong@sinopharm.com
86-021-62800991
Huan Zhou, Master
principal investigator · Co., Ltd Shanghai Institute Of Biological Products

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion